https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
59; 95% CI, 0.79-3.19; P = .20; I2 = 51%). Double-dose oseltamivir did not show statistical benefit on the virologic clearance rate (OR, 1.26; 95% CI, 0.85-1.88; P = .25; I2 = 0%) or the incidence of adverse events (AEs) (OR, 1.52; 95% CI, 0.85-2.72; P = .15; I2 = 59%). What is new and conclusion Current evidence indicates that double-dose oseltamivir does not decrease mortality or have advantages on the outcome of virologic clearance rate and incidence of AEs. However, the finding largely relied on the data from observation
Like
Comment
Share
